-
-
-
-
-
-
-
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscl
-
-
-
-
-
66,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

